Associations between global population health indicators and dialysis variables in the monitoring dialysis outcomes (MONDO) consortium

Blood Purification

Volumn 39, Issue 1-3, 2015, Pages 125-136

  Calice Silva, Viviane ^a,b   Hussein, Rasha ^a   Yousif, Dalia ^a   Zhang, Hanjie ^b   Usvyat, Len ^b,c   Campos, Ludimila G ^a   Von Gersdorff, Gero ^d   Schaller, Mathias ^d   Marcelli, Danielle ^e   Grassman, Aileen ^e   Etter, Michael ^e   Xu, Xiaoqi ^f   Kotanko, Peter ^b   Pecoits Filho, Roberto ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^b RENAL RESEARCH INSTITUTE   (United States)

^c FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e FRESENIUS MEDICAL CARE   (Germany)

^f Fresenius Medical Care Asia Pacific ^*  (Hong Kong)

Author keywords

End stage renal disease; Health indicators; Hemodialysis; Renal replacement therapy

Indexed keywords

ADULT; AGED; CONFERENCE PAPER; EDUCATIONAL STATUS; END STAGE RENAL DISEASE; FEMALE; HEALTH; HEALTH CARE; HEALTH STATUS INDICATOR; HEMODIALYSIS; HUMAN; HUMAN DEVELOPMENT; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; POPULATION RISK; PREVALENCE; PRIORITY JOURNAL; SOCIAL DETERMINANTS OF HEALTH; SOCIOECONOMICS; WORLD HEALTH ORGANIZATION; BODY FLUID; ECONOMICS; FACTUAL DATABASE; HEALTH STATUS; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; PATHOLOGY; RENAL REPLACEMENT THERAPY;

AGED; BODY FLUIDS; DATABASES, FACTUAL; FEMALE; HEALTH STATUS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREVALENCE; RENAL DIALYSIS; SOCIOECONOMIC FACTORS; WORLD HEALTH ORGANIZATION;

EID: 84923089540     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000368980     Document Type: Conference Paper

References (44)

1. Annual Data Report. United States Renal Data System (USRDS) 2013: Chapter 11-13.
2. ERA-EDTA Registry: ERA-EDTA Registry Annual Report 2012. Academic Medical Center, Department of Medical Informatics, Amsterdam, the Netherlands, 2014.
3. Cusumano AM, Garcia-Garcia G, Gonzalez-Bedat MC, Marinovich S, Lugon J, Poblete-Badal H, Elgueta S, Gomez R, Hernandez-Fonseca F, Almaguer M, Rodriguez-Manzano S, Freire N, Luna-Guerra J, Rodriguez G, Bochicchio T, Cuero C, Cuevas D, Pereda C, Carlini R: Latin American Dialysis and Transplant Registry: 2008 prevalence and incidence of end-stage renal disease and correlation with socioeconomic indexes. Kidney Int Suppl 2013; 3: 153-156.
4. Pisoni RL, Greenwood RN: Selected lessons learned from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Contrib Nephrol 2005; 149: 58-68.
5. Lysaght MJ: Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002; 13:S37-S40.
6. Moeller S, Gioberge S, Brown G: ESRD patients in 2001: global overview of patients, treatment modalities and development trends. Nephrol Dial Transplant 2002; 17: 2071-2076.
7. Grassmann A, Gioberge S, Moeller S, Brown G: ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005; 20: 2587-2593.
8. Grassmann A, Gioberge S, Moeller S, Brown G: End-stage renal disease: global demographics in 2005 and observed trends. Artif Organs 2006; 30: 895-897.
9. Rosa-Diez G, Gonzalez-Bedat M, Pecoits-Filho R, et al: Renal replacement therapy in Latin American end-stage renal disease. Clin Kidney J 2014;7:431-436.
10. Jager KJ, Korevaar JC, Dekker FW, et al: The effect of contraindications and patient preference on dialysis modality selection in ESRD patients in The Netherlands. Am J Kidney Dis 2004; 43: 891-899.
11. Chugh KS, Jha V, Chugh S: Economics of dialysis and renal transplantation in the developing world. Transplant Proc 1999;31:3275-3277.
12. Caskey FJ, Kramer A, Elliott RF, Stel VS, Covic A, Cusumano A, Geue C, MacLeod AM, Zwinderman AH, Stengel B, Jager KJ: Global variation in renal replacement therapy for end-stage renal disease. Nephrol Dial Transplant 2011; 26: 2604-2610.
13. Yoshino M, Kuhlmann MK, Kotanko P, et al: International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. J Am Soc Nephrol 2006; 17: 3510-3519.
14. Caskey FJ, Stel VS, Elliott RF, et al: The EVEREST study: an international collaboration. NDT Plus 2010; 3: 28-36.
15. Caskey FJ, Jager KJ: A population approach to renal replacement therapy epidemiology: lessons from the EVEREST study. Nephrol Dial Transplant 2014; 29: 1494-1499.
16. van de Luijtgaarden MW, Jager KJ, Stel VS, Kramer A, Cusumano A, Elliott RF, Geue C, MacLeod AM, Stengel B, Covic A, Caskey FJ: Global differences in dialysis modality mix: the role of patient characteristics, macroeconomics and renal service indicators. Nephrol Dial Transplant 2013; 28: 1264-1275.
17. Chugh KS, Jha V: Differences in the care of ESRD patients worldwide: required resources and future outlook. Kidney Int Suppl 1995; 50:S7-S15.
18. Nissenson AR, Prichard SS, Cheng IK, Gokal R, Kubota M, Maiorca R, Riella MC, Rottembourg J, Stewart JH: ESRD modality selection into the 21st century: the importance of non medical factors. ASAIO J 1997; 43: 143-150.
19. Usvyat LA, Haviv YS, Etter M, Kooman J, Marcelli D, Marelli C, Power A, Toffelmire T, Wang Y, Kotanko P: The MONitoring Dialysis Outcomes (MONDO) initiative. Blood Purif 2013; 35: 37-48.
20. von Gersdorff GD, Usvyat L, Marcelli D, Grassmann A, Marelli C, Etter M, Kooman JP, Power A, Toffelmire T, Haviv YS, Guinsburg A, Barth C, Schaller M, Bayh I, Scatizzi L, Tashman A, Thijssen S, Levin NW, van der Sande FM, Pusey C, Wang Y, Kotanko P: Monitoring dialysis outcomes across the world- The MONDO Global Database Consortium. Blood Purif 2013; 36: 165-172.
21. World Health Statistics-Part III: Global Health Indicators. World Health Organization, 2014, pp 56-175.
22. Khalid Malik, et al: Human Development Report 2014-Sustaining Human Progress: Reducing Vulnerabilities and Building Resilience. United Nations Development Program, 2014.
23. Martinsson A, Andersson C, Andell P, Koul S, Engström G, Smith JG: Anemia in the general population: prevalence, clinical correlates and prognostic impact. Eur J Epidemiol 2014; 29: 489-498.
24. De Vecchi AF, Dratwa M, Wiedemann ME: Healthcare systems and end-stage renal disease (ESRD) therapies-an international review: costs and reimbursement/funding of ESRD therapies. Nephrol Dial Transplant 1999; 14: 31-41.
25. Nutrition in Chronic Renal Failure-KDOQI guideline. Am J Kidney Dis 2000; 35(suppl 2):S9-S1022.
26. Usvyat LA, Barth C, Bayh I, Etter M, von Gersdorff GD, Grassmann A, Guinsburg AM, Lam M, Marcelli D, Marelli C, Scatizzi L, Schaller M, Tashman A, Toffelmire T, Thijssen S, Kooman JP, van der Sande FM, Levin NW, Wang Y, Kotanko P: Interdialytic weight gain, systolic blood pressure, serum albumin, and C-reactive protein levels change in chronic dialysis patients prior to death. Kidney Int 2013; 84: 149-157.
27. Wanner C, Tonelli M; Kidney Disease; Improving Global Outcomes Lipid Guideline Development Work Group Members: KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 2014; 85: 1303-1309.
28. K/DOQI Workgroup: K/DOQI Clinical Practices Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis 2005; 45(suppl 3):S1-S153.
29. Martinsson A, Andersson C, Andell P, Koul S, Engström G, Smith JG: Anemia in the general population: prevalence, clinical correlates and prognostic impact. Eur J Epidemiol 2014; 29: 489-498.
30. Handelman GJ, Kotanko P, Cisternas MG, et al: Hospitalization and mortality in hemodialysis patients: association with hemoglobin variability. Blood Purif 2013; 35: 247-257.
31. KDOQI: KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471-530.
32. Locatelli F, Nissenson AR, Barrett BJ, Walker RG, Wheeler DC, Eckardt KU, Lameire NH, Eknoyan G: Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2008; 74: 1237-1240.
33. de Moraes PT, Figueiredo AE, Campos LG, Olandoski M, Barretti P, Pecoits-Filho R; BRAZPD Investigators: Characterization of the BRAZPD II cohort and description of trends in peritoneal dialysis outcome across time periods. Perit Dial Int 2014, in press.
34. Loghman-Adham M: Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care 2003; 9: 155-171.
35. Yoder LA, Xin W, Norris KC, Yan G: Patient care staffing levels and facility characteristics in U. S. hemodialysis facilities. Am J Kidney Dis 2013; 62: 1130-1140.
36. Eisenstein EL, Sun JL, Anstrom KJ, et al: Do income level and race influence survival in patients receiving hemodialysis? Am J Med 2009; 122: 170-180.
37. Li PK, Chow KM: The cost barrier to peritoneal dialysis in the developing world-an Asian perspective. Perit Dial Int 2001; 21(suppl 3):S307-S313.
38. Jung B, Blake PG, Mehta RL, et al: Attitudes of Canadian nephrologists toward dialysis modality selection. Perit Dial Int 1999; 19: 263-268.
39. Just PM, de Charro FT, Tschosik EA, et al: Reimbursement and economic factors influencing dialysis modality choice around the world. Nephrol Dial Transplant 2008; 23: 2365-2373.
40. Docteur E, Oxley H: Health-care systems: lessons from the reform experience. OECD Health Working Paper No. 9 (Paris, Organization for Economic Co-operation and Development) 2003.
41. Couchoud C, Guihenneuc C, Bayer F, Lemaitre V, Brunet P, Stengel B; REIN Registry: Medical practice patterns and socio-economic factors may explain geographical variation of end-stage renal disease incidence. Nephrol Dial Transplant 2012; 27: 2312-2322.
42. Blake PG: The complex economics of modality selection. Perit Dial Int 2004; 24: 509-511.
43. Dor A, Pauly MV, Eichleay MA, et al: Endstage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF). Int J Health Care Finance Econ 2007; 7: 73-111.
44. Horl WH, de Alvaro F, Williams PF: Healthcare systems and end-stage renal disease (ESRD) therapies-an international review: access to ESRD treatments. Nephrol Dial Transplant 1999; 14: 10-15.